Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes the announcement made by EKF Diagnostics Holdings PLC (“EKF”) this morning (RNS 3845P), declaring the distribution of its Verici Dx Investment Shares to Relevant EKF Shareholders via a distribution in specie.
These shares comprise of 9,098,611 ordinary shares in Verici Dx of £0.001 each and are subject to a Lock-up Period of 365 days from transfer.
Full details can be seen in the EKF announcement here:
Capitalised terms in this announcement carry the same definitions as in the EKF announcement.
Sara Barrington, CEO
Julian Baines, Chairman
Via Walbrook PR
N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Kailey Aliyar / Tom Salvesen
Tel: 020 7496 3000
Walbrook PR Limited
Paul McManus / Sam Allen
Tel: 020 7933 8780 or firstname.lastname@example.org
Mob: 07980 541 893 / 07748 651 727